NCT06467201 - SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of KSHN001126 in Healthy Post-Menopausal Females | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions

Healthy Postmenopausal Women

Interventions

DRUG

KSHN001126 150mg

6 subjects will receive single oral dose of 150mg

DRUG

KSHN001126 300mg

6 subjects will receive single oral dose of 300mg

DRUG

KSHN001126 600mg

6 subjects will receive single oral dose of 600mg

Trial Locations (2)

Advanced Pharma CR, Miami

Health1 Superspeciality Hospital, Ahmedabad